Under what circumstances would you consider LDL apheresis in a kidney transplant patient with FSGS recurrence within three months of transplantation?

LDL apheresis has not been part of our protocol for the treatment of recurrent FSGS. Our protocol is still plasmapheresis x 9 runs, and now considering institution of daratumumab. Protocols are still evolving for this vesiculating problem.